The recall, dated Tuesday, August 25, involves two lots of Baxter International Inc.’s 0.9% Sodium Chloride Injection because the product may contain fiberglass in the solution itself, the company said.
“Intravenous administration of 0.9% Sodium Chloride Injection containing fiberglass particulate matter may lead to serious adverse health consequences,” the company said.
The FDA report said the possible contaminant could cause blockage and clotting of blood vessels, which could cut off blood flow to vital organs and lead to a life-threatening blood clot in the lungs, causing permanent organ damage or death in some cases.
Other reactions could include “local vein irritation, inflammatory reaction, aggravation of preexisting infections, and allergic reactions.” However, no reports of adverse effects have been reported to the company as of Tuesday, August 25.
The recalled lots were distributed between July 31, 2026, and August 3, 2026, to health care providers and distributors in more than a dozen states, including Texas.
“The product is indicated as a source of water and electrolytes and is also indicated for use as a priming solution in hemodialysis procedures,” the FDA recall alert stated.
The lot numbers include Y495523 and Y495523A, with an expiration date of October 31, 2027.
The company said customers who received the products should immediately stop using them and return all affected units to Baxter. Customers with questions can call Baxter Healthcare Center for Service at 888-229-0001 between 7 a.m. and 6 p.m. Central Time, Monday through Friday.
Anyone who experiences health effects should immediately contact a healthcare professional and the FDA’s MedWatch Adverse Event Reporting program by submitting a report online or by calling 1-800-332-1088 to request a reporting form and mailing address.
MySA reached out to the following local hospital systems to see if they had been affected by the recall: